Browsing by title
Now showing items 1550-1569 of 4580
-
Ethical Considerations for the Inclusion of Patient-Reported Outcomes in Clinical Research: The PRO Ethics Guidelines.
(AMER MEDICAL ASSOC, 2022-05-17)IMPORTANCE: Patient-reported outcomes (PROs) can inform health care decisions, regulatory decisions, and health care policy. They also can be used for audit/benchmarking and monitoring symptoms to provide timely care ... -
Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation.
(WILEY, 2018-08-15)Limited epidemiological evidence suggests that the etiology of hormone receptor positive (HR+) breast cancer may differ by levels of histologic grade and proliferation. We pooled risk factor and pathology data on 5,905 HR+ ... -
EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors.
(BMJ PUBLISHING GROUP, 2021-01-01)BACKGROUND: Rheumatic and musculoskeletal immune-related adverse events (irAEs) are observed in about 10% of patients with cancer receiving checkpoint inhibitors (CPIs). Given the recent emergence of these events and the ... -
European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer.
(ELSEVIER, 2022-03-01)BACKGROUND: Homologous recombination repair (HRR) enables fault-free repair of double-stranded DNA breaks. HRR deficiency is predicted to occur in around half of high-grade serous ovarian carcinomas. Ovarian cancers ... -
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma.
(FERRATA STORTI FOUNDATION, 2014-02-01)Multiple myeloma management has undergone profound changes in the past thanks to advances in our understanding of the disease biology and improvements in treatment and supportive care approaches. This article presents ... -
European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment.
(Oxford University Press (OUP), 2022-12-13)AIMS: To develop quality indicators (QIs) for the evaluation of the prevention and management of cancer therapy-related cardiovascular toxicity. METHODS AND RESULTS: We followed the European Society of Cardiology (ESC) ... -
Evaluating a digital tool for supporting breast cancer patients: a randomized controlled trial protocol (ADAPT).
(BMC, 2020-01-15)BACKGROUND: There are a growing number of mHealth tools for breast cancer patients but a lack of scientific evidence for their effects. Recent studies have shown a mix of positive and negative impacts on users. Here we ... -
Evaluating Germline Testing Panels in Southern African Males With Advanced Prostate Cancer.
(HARBORSIDE PRESS, 2023-03-01)BACKGROUND: Germline testing for prostate cancer is on the increase, with clinical implications for risk assessment, treatment, and management. Regardless of family history, NCCN recommends germline testing for patients ... -
Evaluating Imaging Biomarkers of Acquired Resistance to Targeted EGFR Therapy in Xenograft Models of Human Head and Neck Squamous Cell Carcinoma.
(FRONTIERS MEDIA SA, 2018-07-23)Background: Overexpression of EGFR is a negative prognostic factor in head and neck squamous cell carcinoma (HNSCC). Patients with HNSCC who respond to EGFR-targeted tyrosine kinase inhibitors (TKIs) eventually develop ... -
Evaluating MRI biomarkers of tumour hypoxia
(Institute of Cancer Research (University Of London), 2020-12-31)Tumour hypoxia is associated with resistance to radiotherapy and chemotherapy, and represents a major challenge in the treatment of head and neck squamous cell carcinoma (HNSCC). Non-invasive imaging methods to repeatedly ... -
Evaluation of a Dual Isolation Width Acquisition Method for Isobaric Labeling Ratio Decompression.
(AMER CHEMICAL SOC, 2019-03-01)Isobaric labeling is a highly precise approach for protein quantification. However, due to the isolation interference problem, isobaric tagging suffers from ratio underestimation at the MS2 level. The use of narrow isolation ... -
Evaluation of a multi-atlas CT synthesis approach for MRI-only radiotherapy treatment planning.
(ELSEVIER SCI LTD, 2017-03-01)BACKGROUND AND PURPOSE: Computed tomography (CT) imaging is the current gold standard for radiotherapy treatment planning (RTP). The establishment of a magnetic resonance imaging (MRI) only RTP workflow requires the ... -
Evaluation of a novel antibody to define histone 3.3 G34R mutant brain tumours.
(BMC, 2017-06-06)Missense somatic mutations affecting histone H3.1 and H3.3 proteins are now accepted as the hallmark of paediatric diffuse intrinsic pontine gliomas (DIPG), non-brain stem paediatric high grade gliomas (pHGG) as well as a ... -
Evaluation of a urology specialist therapeutic radiographer implemented radiotherapy pathway for prostate cancer patients.
(ELSEVIER SCI LTD, 2021-04-15)INTRODUCTION: The role of the Urology Specialist Therapeutic Radiographer (USTR) was introduced to support a busy NHS uro-oncology practice. Key objectives were to improve patient preparedness for and experience of ... -
Evaluation of APOBEC3B Recognition Motifs by NMR Reveals Preferred Substrates.
(AMER CHEMICAL SOC, 2018-09-21)APOBEC3B (A3B) deamination activity on ssDNA is considered a contributing factor to tumor heterogeneity and drug resistance in a number of human cancers. Despite its clinical impact, little is known about A3B ssDNA substrate ... -
Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES.
(SPRINGER, 2018-02-01)BACKGROUND: Intergroup Exemestane Study (IES) was a randomised study that showed a survival benefit of switching adjuvant endocrine therapy after 2-3 years from tamoxifen to exemestane. This PathIES aimed to assess the ... -
Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer.
(AMER MEDICAL ASSOC, 2019-05-03)IMPORTANCE: Increasing BRCA1 and BRCA2 (collectively termed herein as BRCA) gene testing is required to improve cancer management and prevent BRCA-related cancers. OBJECTIVE: To evaluate mainstream genetic testing using ... -
Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response-Targeted Therapies in Breast Cancer.
(AMER ASSOC CANCER RESEARCH, 2018-01-01)Disruption of Cyclin-Dependent Kinase 12 (CDK12) is known to lead to defects in DNA repair and sensitivity to platinum salts and PARP1/2 inhibitors. However, CDK12 has also been proposed as an oncogene in breast cancer. ... -
An evaluation of contouring and planning methods to expand the role of SBRT with CyberKnife in the treatment of localised prostate and renal cancers
(Institute of Cancer Research (University Of London), 2022-05-31)Technological advancement has led to the substantial evolution of stereotactic body radiotherapy (SBRT). The CyberKnife SBRT platform achieves a high degree of precision through robotic delivery of multiple non-coplanar ...